Gaa na ọdịnaya

Irene Ghobrial

Shí Wikipedia, njikotá édémédé nke onyobulạ

 

Na Machị 2024, ọ jere ozi na kọmitii ODAC wee nyere aka na nkwado nke CiltaCel (Carvykti) na ahịrị nke abụọ nke abụọ Multiple Myeloma.[1] N'Eprel 2024, e pịa ya na ebook ndị na-asụ usoro (usoro usoro) kpara ọtụtụ myeloma nọmba site na usoro. O jiri Gad Getz ngwaọrụ ọhụrụ[2] a na-akpọ MinimuMM-seq nke nwere ike ike ojiji nke ụmị ọkpụkpụ biopsies na ọzọ FISH maka nchoputa na prognosis nke otutu myeloma.

Dr. Ghobrial bụ Onye isi osote onye isi oche maka ọgwụ nnwale, onye nduzi nke Center for Early Detection and Interception of Blood Cancers, onye ndu nke Ghobrial Lab, onye isi nke Lymphoma / Myeloma Cancer Center Program, na prọfesọ nke ọgwụ na Dana-Farber Cancer Institute na Harvard Medical School.

Mbido ndụ na agụmakwụkwọ

[dezie | dezie ebe o si]

Ghobrial biri na Naijiria ruo afọ 13 n'oge ọ bụ nwata wee kwaga Ijipt wee mụọ ọgwụ na Mahadum Cairo . [1] Mgbe ọ gụsịrị akwụkwọ, ọ kwagara Detroit, ebe ọ gụsịrị ọzụzụ ọkachamara ya na Mahadum Wayne State.[2][3] N'afọ 2000, ọ kwagara na Mayo Clinic, Rochester, MN, ebe ya na Robert A. Kyle rụkọrọ ọrụ dị ka onye na-ahụ maka hematology na oncology.[2]

Nnyocha na ọrụ

[dezie | dezie ebe o si]

Dr. Ghobrial bụ dọkịta na sayensị bụ ọkachamara na multiple myeloma na Waldenström macroglobulinemia, ọkachasị na ọnọdụ ndị na-ebute monoclonal gammopathy nke a na-amaghị ama (MGUS) na myeloma.

Nnyocha ahụike na nke ụlọ nyocha ya na-elekwasị anya n'ịghọta usoro ọganihu ọrịa site na ọnọdụ mmalite, gụnyere monoclonal gammopathy nke enweghị nkwenye (MGUS) na myeloma na-ese anwụrụ (SMM) iji gosipụta ọtụtụ myeloma, multiple myeloma (MM). Ebumnuche ya bụ imebi usoro nlekọta ọrịa kansa na myeloma site n'ịduzi nyocha maka nchọpụta n'oge, ịmepụta ihe ọhụrụ na-egosi ihe ize ndụ, na imebi usoro ọgwụgwọ site na nnwale ọgwụgwọ ọhụrụ na myelomas na-ese anwụrụ.

Ruo n'oge na-adịbeghị anya, ụkpụrụ nlekọta maka precursor myeloma bụ nyocha na nlekota. Ndị otu ya nwere mmasị ịghọta ihe ndị na-enye ohere maka ọganihu ọrịa na ịsụgharị nke ahụ n'ime usoro ọgwụgwọ mbụ nke nwere ike imeziwanye nsonaazụ maka ndị ọrịa MM ma ọ bụ gbochie MM ịmalite na mbụ.

Iji mezuo nke a, ọ malitere Center for Early Detection and Interception of Blood Cancers, ebe ndị ọrịa nwere ọnọdụ precursor dị ka MGUS, early myelodysplastic syndromes (MDS), na early chronic lymphocytic leukemia (CLL) na-enweta nchịkọta sample ma na-enyocha ha maka mgbochi nke evolushọn clonal na ọganihu ọrịa.

Ọ mepụtara nnukwu nyocha nyocha nke na-eme ka onye ọrịa dị ike maka ọnọdụ precursor (ọmụmụ PCROWD) nke natara ihe karịrị ndị ọrịa 4,000 na ihe nlele nwetara n'ọtụtụ oge n'oge ọganihu ọrịa. Mgbalị ya n'ọhịa na-ebute ụzọ nyere anyị ohere ịmalite nyocha mbụ maka MGUS / SMM na US. Nnyocha a, nke akpọrọ PROMISE, na-enyocha mmadụ 30,000 nọ n'ihe ize ndụ dị elu nke ibute myeloma, gụnyere ndị Africa America na ndị ikwu mbụ nke ndị ọrịa na-arịa myeloma. [4] [5][6]

Ndị otu ya bụ otu n'ime ndị mbụ nyochara mgbanwe nke mkpụrụ ndụ ihe nketa na mkpụrụ ndụ akpụ nke ọkpụkpụ na mkpụrụ ndụ tumor na-agbasa (CTCs) n'oge ọrịa na-aga n'ihu site na MGUS / SMM ruo myeloma. N'oge na-adịbeghị anya, o gosipụtara site na usoro nke otu mkpụrụ ndụ na mgbanwe na nchịkwa nke mkpụrụ ndụ na-alụso ọrịa ọgụ na-eme n'oge MGUS ma na-aga n'ihu na mgbanwe nke mkpụrụ ndụ ahụike n'oge ọrịa na-agafe site na MGUS gaa na myeloma (gbakwunye ref).

Ihe na-atọ ya ụtọ bụ ịsụgharị nchọpụta ụlọ nyocha ngwa ngwa na ụlọ ọgwụ. Ọ duziri ihe karịrị nnwale ahụike 15 nke ndị nchọpụta malitere ma ugbu a na-elekwasị anya n'ịmepụta ọtụtụ ụzọ mgbochi ziri ezi na MGUS na SMM, na-elekkwu anya na immunotherapy. Ọ bụ onye isi nchọpụta nke mbụ bispecific na nke mbụ CAR-T ule a ga-enyocha na Myeloma na-enweghị mgbaàmà. Nnyocha ndị a na-egosipụta nzaghachi a na-ahụtụbeghị mbụ nke nwere ike imebi ụzọ anyị si agwọ myeloma site na mgbochi ọrịa n'oge kama ịbụ ụkpụrụ nlekọta ugbu a.

N'afọ 2010, ọ natara Robert A. Kyle Award maka nyocha na WM. N'afọ 2011, a họpụtara Ghobrial ka ọ bụrụ onye American Society for Clinical Investigation. N'afọ 2014, ọ natara onyinye Mentor of the Year na Dana-Farber Cancer Institute. N'afọ 2017, ọ natara Ken Anderson Basic and Translational Research Award site na International Myeloma Society maka onye nchọpụta pụtara ìhè n'okpuru afọ 40. N'afọ 2018, e nyere ya $ 10 nde site na Stand Up to Cancer iji guzobe Multiple Myeloma Dream Team, nke bu n'uche ịghọta ihe ndị na-egosi ihe ize ndụ nke ibute myeloma.[7]N'afọ 2022, o nwetakwara onyinye National Cancer Institute Outstanding Investigator Award maka nyocha ọ na-aga n'ihu. Ọ natara onyinye Jan Gosta Waldenstrom na 2022 [AJ3] maka nyocha ya na ọrịa B-cell. N'afọ 2022, e nyere Ghobrial ihe nrite William Dameshek site n'aka American Society of Hematology maka enyemaka sayensị ya n'ọhịa nchọpụta na mgbochi nke malignancies hematological.[8]

Na Jenụwarị 2024, The Harvard Crimson kọrọ na a na-ebo Ghobrial, yana ndị ọkà mmụta sayensị atọ nọ na Dana Faber Cancer Institute, ebubo na ha na-eme ihe ọjọọ na-eme nchọpụta na data adịgboroja.[9] Otú ọ dị, e meela mgbanwe n'akwụkwọ ya n'enweghị ntụgharị ọ bụla na errata emetụtaghị iguzosi ike n'ezi ihe sayensị nke nyocha ndị ahụ e mere na ọmụmụ ihe ndị ahụ.[10][11][12][13][14][15][16][17] Ọ na-aga n'ihu na-elekwasị anya n'ọrụ ya na mpaghara nchọpụta na mgbochi na myeloma.

Na Machị 2024, ọ jere ozi na kọmitii ODAC wee nyere aka na nkwado nke CiltaCel (Carvykti) na ahịrị nke abụọ nke ọgwụgwọ Multiple Myeloma.[1] N'April 2024, e gosipụtara ya na ebook ndị ọkà mmụta sayensị (usoro mgbanwe usoro) gbasara nyochaa ọtụtụ myeloma ọganihu site na usoro. O jiri Gad Getz mepụta usoro ọhụrụ[2] a na-akpọ MinimuMM-seq nke nwere ike dochie ojiji nke ụmị ọkpụkpụ biopsies na teknụzụ FISH maka nchoputa na prognosis nke otutu myeloma..[18]

Edemsibia

[dezie | dezie ebe o si]
  1. ↑ Gatta (2023). "How my training helps me to address health disparities in multiple myeloma: Irene Ghobrial's research on early detection of this type of bone-marrow cancer aims to improve patient outcomes, especially among African Americans" (in en). Nature. DOI:10.1038/d41586-023-01587-9. PMID 37165230. 
  2. ↑ 2.0 2.1 Irene Ghobrial, MD (en). aacr.org. American Association for Cancer Research. Retrieved on 2023-05-15.
  3. ↑ Director, Clinical Investigator Research Program – Dana-Farber (en). physicianresources.dana-farber.org. Retrieved on 2023-05-15.
  4. ↑ Get to Know… Irene Ghobrial, MD (en). Blood Cancers Today. Retrieved on 2024-06-11.
  5. ↑ Smoldering Multiple Myeloma - A Unique New Approach - Dana-Farber (en). physicianresources.dana-farber.org. Retrieved on 2024-06-11.
  6. ↑ El-Khoury (May 2022). "Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study". The Lancet. Haematology 9 (5): e340–e349. DOI:10.1016/S2352-3026(22)00069-2. ISSN 2352-3026. PMID 35344689. 
  7. ↑ Chen (2022-04-21). Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early (en-US). STAT. Retrieved on 2024-06-11.
  8. ↑ Dana-Farber professor receives William Dameshek Prize for multiple myeloma research (en). www.healio.com. Retrieved on 2024-06-11.
  9. ↑ Dana-Farber Cancer Institute Researchers Accused of Manipulating Data. www.thecrimson.com. Retrieved on 2024-06-11.
  10. ↑ Sahin (2024-04-23). "Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002.". Blood Advances 8 (8): 1958. DOI:10.1182/bloodadvances.2024013092. ISSN 2473-9529. PMID 38619855. 
  11. ↑ Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment (February 16, 2024).
  12. ↑ Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia (February 16, 2024).
  13. ↑ Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia (February 16, 2024).
  14. ↑ (2024-06-20) "CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.". Blood 143 (25): 2673. DOI:10.1182/blood.2024025275. ISSN 0006-4971. 
  15. ↑ (2024-07-04) "Pyk2 promotes tumor progression in multiple myeloma.". Blood 144 (1): 124. DOI:10.1182/blood.2024025297. ISSN 0006-4971. 
  16. ↑ (2024-06-20) "P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.". Blood 143 (25): 2675. DOI:10.1182/blood.2024024988. ISSN 0006-4971. 
  17. ↑ (2024-06-20) "RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma.". Blood 143 (25): 2674. DOI:10.1182/blood.2024025276. ISSN 0006-4971. 
  18. ↑ MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Ewepụtara site na "https://ig.wikipedia.org/w/index.php?title=Irene_Ghobrial&oldid=202699"